ONCOLYTICS BIOTECH INC. ANNOUNCES ISSUANCE OF FIRST CANADIAN PATENT

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") has been granted Canadian Patent 2,374,388 entitled "The use of ribozymes in the detection of adventitious agents." The claims provide a method of validating the purity of microbial preparations during manufacturing by detecting adventitious or contaminating viruses using a ribozyme-based assay that is specific for the microorganism being manufactured. The microorganisms can include, amongst others, the reovirus, and modified adeno, herpes, vaccinia, p53 expressing, and vesticular stomatitis viruses.

Yahoo News (http://biz.yahoo.com/prnews/050810/to201.html?.v=8)